Phase 2 Ovarian Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have ovarian cancer, fallopian tube cancer, or primary peritoneal cancer that has come back and is still responding to platinum-based chemotherapy.
• People who have completed at least 2 previous rounds of treatment that included a platinum-based chemotherapy drug.
• People whose most recent chemotherapy course included at least 4 cycles of a platinum-based drug, and whose cancer showed a partial or complete response to that treatment.
• People who have previously received maintenance therapy with bevacizumab or a PARP inhibitor (if they were eligible for it), or for whom a doctor has determined they are not a candidate for these therapies, or who have declined these therapies in writing.
• People who have recovered from the side effects of their previous cancer treatments — generally to a mild level or better, except for hair loss, or nerve-related side effects which may be at a slightly higher level (confirm with trial site).

Who may not be able to join:

• People who have had 4 or more separate rounds of chemotherapy drugs that directly kill cancer cells.
• People who are currently taking high doses of steroids or other immune-suppressing medications within 2 weeks before the trial treatment would start.
• People who have previously been treated with certain types of immune checkpoint therapy (including PD-1, PD-L1, anti-PVRIG, or TIGIT inhibitors, or similar drugs).
• People who have cancer that has spread to the liver, confirmed by scan or biopsy, at the start or end of their most recent platinum-based chemotherapy.
• People who needed fluid drained from the abdomen during the last 2 cycles of their most recent chemotherapy, or at any time after finishing that chemotherapy.
• People who experienced a bowel blockage in the 6 weeks before entering the trial.
• People who have active cancer spread to the brain or the lining of the brain or spinal cord.
• People who have active hepatitis B, hepatitis C, or HIV infection.
• People who have an active bacterial, fungal, or viral infection that is not under control or requires ongoing treatment with antibiotics, antifungals, or antiviral medications.
• People who have received a live virus vaccine within 30 days before the planned start of trial treatment, or who would need one during the trial.
• People who have had a severe allergic or hypersensitivity reaction to a monoclonal antibody medication, or who are allergic to any ingredient in the trial drugs.
• People who have another serious or unstable medical condition happening at the same time.
• People who have any other condition that, in the treating doctor's judgement, would make participation unsafe or affect the trial's results.
• People who are currently in, or have recently been in, another clinical trial and received an experimental treatment or used an experimental device within 4 weeks before the first dose of this trial's treatment.
• People who are pregnant, breastfeeding, or planning to become pregnant during the trial period.

Important: Always verify eligibility with the trial site directly before applying.